Cardiology
Assessing Cardiovascular Risks Associated with Bruton’s Tyrosine Kinase Inhibitors: Insights from a Meta-Analysis of Phase 3 Trials
This meta-analysis of 17 Phase 3 RCTs reveals that BTK inhibitors, primarily ibrutinib, increase the risk of non-fatal ischemic cardiovascular events in patients with B-cell malignancies, highlighting important safety considerations.
